The country’s largest pharmaceutical manufacturer Panacea Biotech has started production of the Russian vaccine Sputnik-V in collaboration with the Russian Direct Investment Fund (RDIF). RDIF said in a statement that Panacea Biotech, a pharmaceutical company of India, will produce 100 million vaccine doses every year.
The first batch of Sputnik vaccine made at the Baddi Situation plant of Panacea Biotech will be sent to the Gamalia Institute of Russia for quality assessment. According to the Russian RDIF, full scale production of the vaccine will start in India soon. RDIF said in a statement – The first batch of vaccine prepared by Panacea Biotech will be sent to Gamleya, Moscow Institute to develop Sputinak-V for quality controls.
In April this year, Sputnik-V vaccine has been registered in India. Earlier, Panacea Biotech announced that RDIF and Panacea Biotech (one of the leading pharmaceutical manufacturers in India) would produce 100 million doses of Sputinik-V every year.